J&J is appealing a $572 million opioid verdict in Oklahoma, but as that process plays out, state politicians contend the drugmaker should be on the line for future abatement costs. Lawyers for the company say the argument is “unnecessary, redundant, and unpersuasive."
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,